C. Difficile

Updated review and meta-analysis identifies the classes of antibiotics most strongly linked to healthcare facility-associated Clostridioides difficile infection.

This prognostic marker might not be an adequate reason to test for Clostridium difficile in hospitalized patients.

Oral vancomycin prophylaxis was found by a small study to prevent C diff infection in thoracic transplant patients.

The study determined that acid-base disturbances like can influence the risk of a C diff infection after cardiac surgery is performed

Clostridium difficile infection (CDI) is a leading cause of healthcare-associated infections and the clinical spectrum ranges from asymptomatic colonization to toxic megacolon and fulminant colitis.

Infection control efforts to combat hospital-onset Clostridioides difficile infection may be better spent on health care workers’ hand hygiene compliance and environmental cleaning than on visitor contact precautions, a new study suggests.

Recruitment for a phase 2 trial of a novel antibiotic against Clostridium difficile (C diff) is proceeding after phase 1 demonstrated safety and tolerability.

Rates of serious clinical complications of Clostridioides difficile infection rose as the number of recurrent infections increased, underscoring the importance of advancing new treatments to prevent recurrence of the disease, a recent study in SAGE Open Medicine found.

According to one new study, proton-pump inhibitors (PPI) exposure demonstrated a moderate increase in the risk of community-acquired C diff infection.

Clostridioides difficile thrives in an environment of inflammation which found that inflammation provides nutrients for C. diff and creates an inhospitable environment for competing bacteria.

Investigators said their paper was the first systematic review and meta-analysis of C diff infection diagnostic methods in Korea.

An orally administered adsorbent to prevent antibiotic disruption of intestinal flora enters phase 3 trial against clostridium difficile (C diff) in patients with hematologic malignancies.

Contemporary care guidelines for this bacterium in geriatrics needs to be followed more closely, one study found.

Empiric broad-spectrum antimicrobial therapy, including coverage of MRSA and Pseudomonas aeruginosa, is generally recommended for healthcare-associated infections.

The bowel resting strategy might reduce switching from metronidazole to vancomycin among patients with Clostridioides difficile infection, but it might not reduce mortality or recurrence, a new study found.

Therapies in the pipeline to treat C. difficile and closing thoughts on what is most exciting, in regards to better prevention and management of the condition, moving forward.

Current barriers associated with the use of fecal microbiota transplantation for C. difficile infections.

Healthcare experts comment on current data associated with emerging microbiota therapies that are currently under study for the treatment of C. difficile infections.

Panelists discuss the use of fecal microbiota transplantation as treatment for eligible patients with C. difficile.

Current gaps in the prevention/treatment of C. difficile infections, as highlighted by leading healthcare professionals.

The rationale for using bezlotoxumab as treatment for certain patients with C. difficile infections and current limitations that are impacting its use in clinical practice.

Implications for prescribing vancomycin or fidaxomicin to treat C. difficile infections.

A discussion on fidaxomicin as treatment for C. difficile infections and clinician feedback on current challenges that impact its use in clinical practice.

Important factors to consider when selecting an appropriate therapy to treat C. difficile.